SEARCH

SEARCH BY CITATION

References

  • 1
    Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 5129.
  • 2
    Suau A, Bonnet R, Sutren M, et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol 1999; 65: 4799807.
  • 3
    Blaut M, Collins MD, Welling GW, Dore J, van Loo J, de Vos W. Molecular biological methods for studying the gut microbiota: the EU human gut flora project. Br J Nutr 2002; 87(Suppl. 2): S20311.
  • 4
    Marteau P, Pochart P, Dore J, Bera-Maillet C, Bernalier A, Corthier G. Comparative study of bacterial groups within the human cecal and fecal microbiota. Appl Environ Microbiol 2001; 67: 493942.
  • 5
    Matsuki T, Watanabe K, Fujimoto J, et al. Quantitative PCR with 16S rRNA-gene-targeted species-specific primers for analysis of human intestinal bifidobacteria. Appl Environ Microbiol 2004a; 70: 16773.
  • 6
    Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R. Use of 16S rRNA Gene-Targeted Group-Specific Primers for Real-Time PCR Analysis of Predominant Bacteria in Human Feces. Appl Environ Microbiol 2004b; 70: 72208.
  • 7
    Salminen S, Bouley C, Boutron-Ruault M-C, et al. Functional food science and gastrointestinal physiology and function. British Journal of Nutrition 1998; 80(Suppl. 1): S14771.
  • 8
    Yoshioka H, Isaki K, Fujita K. Development and differences of intestinal flora in the neonatal period in breast-fed and bottle-fed infants. Pediatrics 1983; 72: 31721.
  • 9
    Harmsen HJ, Wildeboer-Veloo AC, Raangs GC, et al. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J Pediatr Gastroenterol Nutr 2000; 30: 617.
  • 10
    Cummings JH, Macfarlane GT. Gastrointestinal effects of prebiotics. Br J Nutr 2002; 87(Suppl. 2): S14551.
  • 11
    Bouhnik Y, Raskine L, Simoneau G, et al. The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study. Am J Clin Nutr 2004; 80: 165864.
  • 12
    Adams MR, Marteau P. On the safety of lactic acid bacteria from food (Letter to the editor). Intl J Fd Microbiol 1995; 27: 2634.
  • 13
    Ishibashi N, Yamazaki S. Probiotics and safety. Am J Clin Nutr 2001; 73: 465S70S.
  • 14
    Makelainen H, Tahvonen R, Salminen S, Ouwehand AC. In vivo safety assessment of two Bifidobacterium longum strains. Microbiol Immunol 2003; 47: 9114.
  • 15
    Borriello SP, Hammes WP, Holzapfel W, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003; 36: 77580.
  • 16
    Holzapfel WH, Haberer P, Geisen R, Bjorkroth J, Schillinger U. Taxonomy and important features of probiotic microorganisms in food and nutrition. Am J Clin Nutr 2001; 73: 365S73S.
  • 17
    Miyake T, Watanabe K, Watanabe T, Oyaizu H. Phylogenetic analysis of the genus Bifidobacterium and related genera based on 16S rDNA sequences. Microbiol Immunol 1998; 42: 6617.
  • 18
    European commission (Health and Consumer protection directorate-general). Qualified Presumption of Safety. On a Generic Approach to the Safety Assessment of micro-organisms Used in Feed/food and Feed/food Production. http://www.efsa.eu.int/science/colloquium_series/no2_qps/610/colloq02_sanco_discuss_en1.pdf.
  • 19
    FAO/WHO. Report of a Joint FAO/WHO Expert Group. Health and Nutritional Properties of Probiotics in Food Including Powder milk with Live Lactic Acid Bacteria. Cordoba, Argentina: Food and Agricultural Organization of the United Nations, World Health Organization, 1–4 October 2001, http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf.
  • 20
    Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125: 140112.
  • 21
    Pochart P, Marteau P, Bouhnik Y, Goderel I, Bourlioux P, Rombard JC. Survival of bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion. Am J Clin Nutr 1992; 55: 7880.
  • 22
    Bouhnik Y, Pochart P, Marteau P, Arlet G, Goderel I, Rambaud JC. Fecal recovery in humans of viable Bifidobacterium sp. ingested in fermented milk. Gastroenterology 1992; 102: 8758.
  • 23
    Berrada N, Lelemand JF, Laroche G, Thouvenot P, Piaia M. Bifidobacterium from fermented milks: survival during gastric transit. J Dairy Sci 1991; 74: 40913.
  • 24
    Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr 2001; 73: 399S405S.
  • 25
    Pochart P, Marteau P, Bissetti N, Goderel I, Bourlioux P, Rombard J. Isolement des bifidobactéries dans les selles après ingestion prolongée de lait au bifidus (LB). Méd Mal Infect 1990; 758 (special issue).
  • 26
    Duez H, Pelletier C, Cools S, et al. A colony immunoblotting method for quantitative detection of a Bifidobacterium animalis probiotic strain in human faeces. Journal of Applied Microbiology 2000; 88: 101927.
  • 27
    Marteau P, Pochart P, Bouhnik Y, Zidi S, Goderel I, Rambaud JC. Survival of Lactobacillus acidophilus and Bifidobacterium sp. in the small intestine following ingestion in fermented milk. A rational basis for the use of probiotics in man. Gastroenterol Clin Biol 1992; 16: 2528.
  • 28
    Kullen MJ, Amann MM, O'Shaughnessy MJ, O'Sullivan DJ, Busta FF, Brady LJ. Differentiation of ingested and endogenous bifidobacteria by DNA fingerprinting demonstrates the survival of an unmodified strain in the gastrointestinal tract of humans. J Nutr 1997; 127: 8994.
  • 29
    Marteau PR. Probiotics in clinical conditions. Clin Rev Allergy Immunol 2002; 22: 25573.
  • 30
    Bouvier M, Meance S, Bouley C, Berta JL, Grimaud JC. Effects of consumption of a milk fermented by the probiotic strain Bifidobacterium animalis DN-173 010 on colonic transit times in healthy humans. Bioscience Microflora 2001; 20: 4348.
  • 31
    Marteau P, Cuillerier E, Meance S, et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double- blind, randomized, controlled study. Aliment Pharmacol Th 2002; 16: 58793.
  • 32
    Meance S, Cayuela C, Raimondi A, Turchet P, Lucas C, Antoine JM. Recent advances in the use of functional foods: effects of the commercial fermented milk with Bifidobacterium animalis strain DN-173 010 and yoghurt strains on gut transit time in the elderly. Microbial Ecology in Health and Disease 2003; 15: 1522.
  • 33
    Meance S, Cayuela C, Turchet P, Raimondi A, Lucas C, Antoine JM. A fermented milk with a bifidobacterium probiotic strain DN-173 010 shortened oro-fecal gut transit time in elderly. Microbial Ecology in Health and Disease 2001; 13: 21722.
  • 34
    Mortensen PB, Clausen MR. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol Suppl 1996; 216: 13248.
  • 35
    Bugaut M, Bentejac M. Biological effects of short-chain fatty acids in nonruminant mammals. Annu Rev Nutr 1993; 13: 21741.
  • 36
    Boffa LC, Lupton JR, Mariani MR, et al. Modulation of colonic epithelial cell proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats. Cancer Res 1992; 52: 590612.
  • 37
    Cummings JH. Short chain fatty acids. In: GibsonGR, MacfarlaneGT, eds. Human Colonic Bacteria: Role in Nutrition, Physiology and Pathology. CRC Press: Boca Raton, 1995: 10130.
  • 38
    Duncan SH, Louis P, Flint HJ. Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. Appl Environ Microbiol 2004; 70: 58107.
  • 39
    Crittenden RG, Martinez NR, Playne MJ. Synthesis and utilisation of folate by yoghurt starter cultures and probiotic bacteria. Int J Food Microbiol 2003; 80: 21722.
  • 40
    Krause LJ, Forsberg CW, O'Connor DL. Feeding human milk to rats increases Bifidobacterium in the cecum and colon which correlates with enhanced folate status. J Nutr 1996; 126: 150511.
  • 41
    Lievin V, Peiffer I, Hudault S, et al. Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 2000; 47: 64652.
  • 42
    Gibson GR, Wang X. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J Appl Bacteriol 1994; 77: 41220.
  • 43
    Fujiwara S, Hashiba H, Hirota T, Forstner JF. Proteinaceous factor(s) in culture supernatant fluids of bifidobacteria which prevents the binding of enterotoxigenic Escherichia coli to gangliotetraosylceramide. Appl Environ Microbiol 1997; 63: 50612.
  • 44
    Perdigon G, Alvarez S, Rachid M, Aguero G, Gobbato N. Immune system stimulation by probiotics. J Dairy Sci 1995; 78: 1597606.
  • 45
    Duffy LC, Zielezny MA, Riepenhoff-Talty M, et al. Reduction of virus shedding by B. bifidum in experimentally induced MRV infection. Statistical application for ELISA. Dig Dis Sci 1994; 39: 233440.
  • 46
    Duffy LC, Zielezny MA, Riepenhoff-Talty M, et al. Effectiveness of Bifidobacterium bifidum in mediating the clinical course of murine rotavirus diarrhea. Pediatr Res 1994; 35: 6905.
  • 47
    Yamazaki S, Tsuyuki S, Akashiba H, et al. Immune response of Bifidobacterium-monoassociated mice. Bifidobacterio Microflora 1991; 10: 1931.
  • 48
    Yamazaki S, Machii K, Tsuyuki S, Momose H, Kawashima T, Ueda K. Immunological responses to monoassociated Bifidobacterium longum and their relation to prevention of bacterial invasion. Immunology 1985; 56: 4350.
  • 49
    Tomoda T, Nakano Y, Kageyama T. Intestinal Candida overgrowth and Candida infection in patients with leukemia: effect of Bifidobacterium administration. Bifidobacteria Microflora 1998; 7: 7174.
  • 50
    Yasui H, Kiyoshima J, Ushijima H. Passive protection against rotavirus-induced diarrhea of mouse pups born to and nursed by dams fed Bifidobacterium breve YIT4064. J Infect Dis 1995; 172: 4039.
  • 51
    Brandtzaeg P, Halstensen TS, Kett K, et al. Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterology 1989; 97: 156284.
  • 52
    Brandtzaeg P. Molecular and cellular aspects of the secretory immunoglobulin system. Apmis 1995; 103: 119.
  • 53
    Sanderson IR, Walker WA. Uptake and transport of macromolecules by the intestine: possible role in clinical disorders (an update). Gastroenterology 1993; 104: 62239.
  • 54
    Ouwehand A, Isolauri E, Salminen S. The role of the intestinal microflora for the development of the immune system in early childhood. Eur J Nutr 2002; 41(Suppl. 1): I327.
  • 55
    Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2003; 17: 75573.
  • 56
    Schiffrin EJ, Rochat F, Link-Amster H, Aeschlimann JM, Donnet-Hughes A. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci 1995; 78: 4917.
  • 57
    Schiffrin EJ, Brassart D, Servin AL, Rochat F, Donnet-Hughes A. Immune modulation of blood leukocytes in humans by lactic acid bacteria: criteria for strain selection. Am J Clin Nutr 1997; 66: 515S20S.
  • 58
    De Simone C, Ciardi A, Grassi A, et al. Effect of Bifidobacterium bifidum and Lactobacillus acidophilus on gut mucosa and peripheral blood B lymphocytes. Immunopharmacol Immunotoxicol 1992; 14: 33140.
  • 59
    de Roos NM, Katan MB. Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998. Am J Clin Nutr 2000; 71: 40511.
  • 60
    Moreau MC, Bisetti N, Dubuquoy C. Immunomodulating properties of a strain of Bifidobacterium used as probiotic on the fecal and cellular intestinal IgA antirotavirus responses in mice. In: FondationBN, ed. Functional Foods: The Consumer, the Products and the Evidence. Cambridge: The Royal Society of Chemistry, 1998: 4751.
  • 61
    Moreau MC, Gaboriau-Routhiau V, Dubuquoy C, Bisetti N, Bouley C, Prevoteau H. Modulating properties of intestinal bacterial strains, Escherichia coli and Bifidobacterium, on two specific immune responses generated by the gut, i.e oral tolerance to ovalbumine and intestinal IgA anti-rotavirus response, in gnotobiotic mice. In: TalwarG, NathI, GangulyN, RaoK, eds. International Congress of Immunology. New Delhi, India: Monduzzi, 1998: 40711.
  • 62
    Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994; 344: 10469.
  • 63
    Phuapradit P, Varavithya W, Vathanophas K, et al. Reduction of rotavirus infection in children receiving bifidobacteria-supplemented formula. J Med Assoc Thai 1999; 82(Suppl. 1): S438.
  • 64
    Chouraqui JP, Van Egroo LD, Fichot MC. Acidified milk formula supplemented with Bifidobacterium lactis: impact on infant diarrhea in residential care settings. J Pediatr Gastroenterol Nutr 2004; 3: 28892.
  • 65
    Chouraqui JP, Van Egroo LD, Fichot MC. Acidified milk formula supplemented with Bifidobacterium lactis: impact on infant diarrhea in residential care settings. J Pediatr Gastroenterol Nutr 2004; 38: 28892.
  • 66
    Bhatia SJ, Kochar N, Abraham P, Nair NG, Mehta AP. Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro. J Clin Microbiol 1989; 27: 232830.
  • 67
    Jack RW, Tagg JR, Ray B. Bacteriocins of gram-positive bacteria. Microbiol Rev 1995; 59: 171200.
  • 68
    Cremonini F, Di Caro S, Santarelli L, et al. Probiotics in antibiotic-associated diarrhoea. Dig Liver Dis 2002; 34(Suppl. 2): S7880.
  • 69
    Orrhage K, Sjostedt S, Nord CE. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. J Antimicrob Chemother 2000; 46: 60312.
  • 70
    Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004; 7: 5962.
  • 71
    Kruis W. Review article: antibiotics and probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20(Suppl. 4): 7578.
  • 72
    Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 162033.
  • 73
    Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305309.
  • 74
    Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL# 3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 10814.
  • 75
    Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 12029.
  • 76
    Laake KO, Bjorneklett A, Aamodt G, et al. Outcome of four weeks’ intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol 2005; 40: 4351.
  • 77
    Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003; 22: 5663.
  • 78
    Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004; 20: 113341.
  • 79
    Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005; 54: 242249.
  • 80
    Hamilton-Miller JM. Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microb Ecol Health Dis 2001; 13: 2126.
  • 81
    O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 54151.
  • 82
    Trichopoulos D, Li FP, Hunter DJ. What causes cancer? Sci Am 1996; 275: 807.
  • 83
    Tavan E, Cayuela C, Antoine JM, Trugnan G, Chaugier C, Cassand P. Effects of dairy products on heterocyclic aromatic amine-induced rat colon carcinogenesis. Carcinogenesis 2002; 23: 47783.
  • 84
    Goldin BR, Swenson L, Dwyer J, Sexton M, Gorbach SL. Effect of diet and Lactobacillus acidophilus supplements on human fecal bacterial enzymes. J Natl Cancer Inst 1980; 64: 25561.
  • 85
    Goldin BR. Intestinal microflora: metabolism of drugs and carcinogens. Ann Med 1990; 22: 438.
  • 86
    Ling WH, Korpela R, Mykkanen H, Salminen S, Hanninen O. Lactobacillus strain GG supplementation decreases colonic hydrolytic and reductive enzyme activities in healthy female adults. J Nutr 1994; 124: 1823.
  • 87
    Marteau P, Pochart P, Flourie B, et al. Effect of chronic ingestion of a fermented dairy product containing Lactobacillus acidophilus and Bifidobacterium bifidum on metabolic activities of the colonic flora in humans. Am J Clin Nutr 1990; 52: 6858.
  • 88
    Pedrosa MC, Golner BB, Goldin BR, Barakat S, Dallal GE, Russell RM. Survival of yogurt-containing organisms and Lactobacillus gasseri (ADH) and their effect on bacterial enzyme activity in the gastrointestinal tract of healthy and hypochlorhydric elderly subjects. Am J Clin Nutr 1995; 61: 3539.
  • 89
    Rafter J, Govers M, Martel P, et al. PASSCLAIM – diet-related cancer. Eur J Nutr 2004; 43(Suppl. 2): II4784.
  • 90
    Walker R. Nitrates, nitrites and N-nitrosocompounds: a review of the occurrence in food and diet and the toxicological implications. Food Addit Contam 1990; 7: 71768.
  • 91
    Cheah PY. Hypotheses for the etiology of colorectal cancer – an overview. Nutr Cancer 1990; 14: 513.
  • 92
    Rowland IR, Grasso P. Degradation of N-nitrosamines by intestinal bacteria. Appl Microbiol 1975; 29: 712.
  • 93
    Orrhage K, Sillerstrom E, Gustafsson JA, Nord CE, Rafter J. Binding of mutagenic heterocyclic amines by intestinal and lactic acid bacteria. Mutat Res 1994; 311: 23948.
  • 94
    Saikali J, Picard C, Freitas M, Holt P. Fermented milks, probiotic cultures, and colon cancer. Nutr Cancer 2004; 49: 1424.
  • 95
    Bouhnik Y, Flourie B, Andrieux C, Bisetti N, Briet F, Rambaud JC. Effects of Bifidobacterium sp fermented milk ingested with or without inulin on colonic bifidobacteria and enzymatic activities in healthy humans. Eur J Clin Nutr 1996; 50: 26973.
  • 96
    Andrieux CM, Cayuela C, Antoine JM. Metabolic characteristics of the faecal microflora in humans from three age groups. Scand J Gastroenterol 2002; 37: 7928.
  • 97
    Ayanaba A, Alexander M. Microbial formation of nitrosamines in vitro. Appl Microbiol 1973; 25: 8628.
  • 98
    Tavan E, Cayuela C, Antoine JM, Cassand P. Antimutagenic activities of various lactic acid bacteria against food mutagens: heterocyclic amines. Journal of Dairy Research 2002; 69: 33541.
  • 99
    Grill JP, Crociani J, Ballongue J. Effect of bifidobacteria on nitrites and nitrosamines. Lett Appl Microbiol 1995; 20: 32830.
  • 100
    Midtvedt T, Norman A. Bile acid transformations by microbial strains belonging to genera found in intestinal contents. Acta Pathol Microbiol Scand 1967; 71: 62938.
  • 101
    Grill JP, Manginot-Durr C, Schneider F, Ballongue J. Bifidobacteria and probiotic effects: action of Bifidobacterium species on conjugated bile salts. Curr Microbiol 1995; 31: 237.
  • 102
    Tanaka H, Doesburg K, Iwasaki T, Mierau I. Screening of lactic acid bacteria for bile salt hydrolase activity. J Dairy Sci 1999; 82: 25305.
  • 103
    Brady LJ, Gallaher DD, Busta FF. The role of probiotic cultures in the prevention of colon cancer. J Nutr 2000; 130: 410S4S.
  • 104
    Lepercq P. Increasing Ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteria. Br J Nutr 2005; 93: 4579.
  • 105
    Lepercq P. Bifidobacterium animalis strain DN-173 010 hydrolyses bile salts in the gastrointestinal tract of pigs. Scand J Gastroenterol 2004; 39: 126671.
  • 106
    Roncucci L. Early events in human colorectal carcinogenesis. Aberrant crypts and microadenoma. Ital J Gastroenterol 1992; 24: 498501.
  • 107
    Thoreux K, Senegas BF, Bernard PF, et al. Modulation of proliferation, second messenger levels, and morphotype expression of the rat intestinal epithelial cell line IEC-6 by fermented milk. J. Dairy Sci 1996; 79: 3343.
  • 108
    Abdelali H, Cassand P, Soussotte V, Daubeze M, Bouley C, Narbonne JF. Effect of dairy products on initiation of precursor lesions of colon cancer in rats. Nutr Cancer 1995; 24: 12132.
  • 109
    Abdelali H, Cassand P, Soussotte V, Koch-Bocabeille B, Narbonne JF. Antimutagenicity of components of dairy products. Mutat Res 1995; 331: 13341.
  • 110
    Cassand P, Abdelali H, Bouley C, Denariaz G, Narbonne JF. Inhibitory effect of dairy products on the mutagenicities of chemicals and dietary mutagens. J Dairy Res 1994; 61: 54552.
  • 111
    Challa A, Rao DR, Chawan CB, Shackelford L. Bifidobacterium longum and lactulose suppress azoxymethane-induced colonic aberrant crypt foci in rats. Carcinogenesis 1997; 18: 51721.
  • 112
    Gallaher DD, Stallings WH, Blessing LL, Busta FF, Brady LJ. Probiotics, cecal microflora, and aberrant crypts in the rat colon. J Nutr 1996; 126: 136271.
  • 113
    Pool-Zobel BL, Neudecker C, Domizlaff I, et al. Lactobacillus- and Bifidobacterium-mediated antigenotoxicity in the colon of rats. Nutr Cancer 1996; 26: 36580.
  • 114
    Wollowski I, Ji ST, Bakalinsky AT, Neudecker C, Pool-Zobel BL. Bacteria used for the production of yogurt inactivate carcinogens and prevent DNA damage in the colon of rats. J Nutr 1999; 129: 7782.
  • 115
    Reddy BS, Rivenson A. Inhibitory effect of Bifidobacterium longum on colon, mammary, and liver carcinogenesis induced by 2-amino-3-methylimidazo[4,5-f]quinoline, a food mutagen. Cancer Res 1993; 53: 39148.
  • 116
    Singh J, Rivenson A, Tomita M, Shimamura S, Ishibashi N, Reddy BS. Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis 1997; 18: 83341.
  • 117
    Kulkarni N, Reddy BS. Inhibitory effect of Bifidobacterium longum cultures on the azoxymethane-induced aberrant crypt foci formation and fecal bacterial beta-glucuronidase. Proc Soc Exp Biol Med 1994; 207: 27883.
  • 118
    Baricault L, Denariaz G, Houri JJ, Bouley C, Sapin C, Trugnan G. Use of HT-29, a cultured human colon cancer cell line, to study the effect of fermented milks on colon cancer cell growth and differentiation. Carcinogenesis 1995; 16: 24552.
  • 119
    Jian W. New approach to phylogenic analysis of the genus Bifidobacterium based on partial HSP60 gene sequences. Int J Syst Evol Microbiol 2001; 51: 16338.
  • 120
    Roller M, Femia AP, Caderni G, Rechkemmer G, Watzl B. Intestinal immunity of rats with colon cancer is modulated by oligofructose-enriched inulin combined with Lactobacillus rhamnosus and Bifidobacterium lactis. Br J Nutr 2004; 92: 9318.
  • 121
    Van der Meulin R, Avonts L, De Vuyst L. Short fractions of oligofructose are preferentially metabolized by Bifidobacterium animalis DN-173 010. App Environ Microbiol 2004; 70: 192330.